Evaluation of the effect of trans sodium crocetinate and crocetin on reperfusion injury in acute myocardial infarction with ST-segment elevation: A double-blind, randomized, placebo-controlled clinical trial | ||
| Avicenna Journal of Phytomedicine | ||
| مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 21 اردیبهشت 1404 اصل مقاله (953.77 K) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2025.26046 | ||
| نویسندگان | ||
| Ghazaleh Elahabadi1؛ Arash Gholoobi2؛ Javad Ramezani2؛ Ali Eshraghi2؛ Reza Javidi Dasht bayaz2؛ Vahid Ghavami3؛ Majid Sezavar Dokht Farough4؛ Amirhooshang Mohamadpoor5؛ Hossein Hosseinzadeh* 6، 7 | ||
| 1Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 2Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 3Department of Bio statistics, Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 4. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 5Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 6Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 7Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| چکیده | ||
| Objective: This randomized, double-blind trial evaluated trans sodium crocetinate (TSC)—a crocetin-derived antioxidant and crocetin with potential cardioprotective effects—on reperfusion injury in 90 ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI). Materials and Methods: Patients received either TSC (0.5 mg/kg injection pre-PPCI + 7.5 mg crocetin tablets for 3 days) or placebo. The primary outcome was ≥ 70% ST-segment resolution 1-hr post-PPCI. Secondary outcomes included corrected thrombolysis in myocardial infarction frame count (CTIMIFC), arrhythmia rates, and echocardiographic parameters (left ventricular ejection fraction (LVEF) and LV size). Results: ST-segment resolution occurrence was significantly higher in the TSC group versus placebo (p=0.018). There was no difference in CTIMIFC between the two groups. Echocardiographic parameters were similar between the TSC and placebo groups. Although not statistically significant, the frequency of supraventricular and ventricular arrhythmias was lower in the TSC group. Adverse drug effects were comparable between the two groups. Conclusion: TSC (0.5 mg/kg injection pre-PPCI + 7.5 mg crocetin tablets for 3 days) administration improved myocardial reperfusion, as evidenced by enhanced ST-segment resolution, suggesting reduced reperfusion injury in STEMI patients post-PPCI. While no benefits were observed in CTIMIFC or cardiac remodeling, the safety profile and primary outcome results support further investigation. Larger trials are needed to confirm efficacy and assess long-term clinical impacts. | ||
| کلیدواژهها | ||
| Trans sodium crocetinate Crocetin Reperfusion injury ST؛ elevation myocardial infarction | ||
|
آمار تعداد مشاهده مقاله: 29 تعداد دریافت فایل اصل مقاله: 17 |
||